Abstract
|
Background
Studies which have sought to explore the associations between diabetes and
cancer have produced heterogeneous results and there is a paucity of evidence
related to glycated haemoglobin (HbA1c) and cancer risk. Methods Initial
analyses utilised data from the Health Survey for England (HSE) and SHeS
combined linked to mortality and Cancer Registry data (n=204,533, including
7,199 with diabetes) to explore the associations between diabetes, HbA1c and
cancer incidence and mortality. Additional analyses used linked Whitehall I
data (n= 19,019, including 237 with diabetes). Odds Ratios (ORs), Hazard
Ratios and 95% Confidence Intervals (CI) were estimated adjusted for a range
of confounding factors using logistic, multinomial and Cox regression. Results
18,310 deaths occurred within the HSE/SHeS follow-up period (4,997 from
cancer). The adjusted OR for cancer among those with diabetes was 1.27, CI
1.12-1.43. Raised HbA1c was associated with an excess risk of
dying/developing cancer; diabetes and HbA1c were associated with a number of
site-specific cancers. When analyses were stratified by cardiovascular
disease (CVD) baseline status, only those with diabetes who did not report
CVD had a statistically significant excess in cancer mortality (adjusted OR:
1.27, 1.08-1.48). There were also sex differences in cancer incidence and
mortality risk. 81% of Whitehall I participants died during follow-up
(including 4,076 from cancer). These results did not replicate the initial
analyses in finding no association between diabetes and cancer mortality
-this is likely to relate to the age of the two cohorts and the differences
in CVD mortality and incidence. Conclusion The association of diabetes and
HbA1c with increased cancer incidence and mortality was not consistent across
studies or population groups. Differences in risk by sex and CVD status
suggest the need for health professionals to tailor services to take account
of the individual circumstances of their diabetic patients.
|